Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 11/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.35 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL589241 | 0.89 | FAAH (0.40) | PNMTADRA2AADRA2BADRA2CSRD5A1 | |
| SCHEMBL1027767 | 0.81 | NPY5R (0.41) | ADRA2C | |
| SCHEMBL22534359 | 0.80 | PNMT (0.41) | PNMTADRA2AADRA2BADRA2CSRD5A1 | |
| SCHEMBL1791020 | 0.79 | PNMT (0.40) | PNMT | |
| SCHEMBL30787846 | 0.74 | AAK1 (0.38) | PNMTADRA2AADRA2BADRA2CMETAP1 | |
| SCHEMBL22547916 | 0.74 | AAK1 (0.38) | PNMTADRA2AADRA2BADRA2CMETAP1 | |
| SCHEMBL10617679 | 0.74 | KDM4E (0.36) | — | |
| SCHEMBL17746131 | 0.73 | MCHR1 (0.33) | PNMTADRA2AADRA2BADRA2CPRMT5 | |
| SCHEMBL1827400 | 0.73 | SRD5A1 (0.40) | SRD5A1SRD5A2 | |
| SCHEMBL354165 | 0.73 | DRD2 (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-7939528-B2 | Heterocycle compounds | GLAXOSMITHKLINE LLC (US) | 2011-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | PNMT 486/4885ADRA2A 13/4885ADRA2B 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.